Vanda Pharmaceuticals shares surge 11.35% after-hours as FDA lifts partial clinical hold on Tradipitant motion sickness trials.

Vanda Pharmaceuticals (NASDAQ:VNDA) surged 11.35% in after-hours trading following the U.S. Food and Drug Administration’s decision to lift a partial clinical hold on its motion sickness drug tradipitant. The FDA agreed with Vanda’s argument that motion sickness is an acute condition, eliminating the need for an additional six-month dog toxicity study. This resolution, achieved through a collaborative framework established in October 2025, allows Vanda to advance clinical trials and maintains the New Drug Application review on track for a December 30, 2025, PDUFA date. The decision positions tradipitant as a potential first new pharmacologic treatment for motion sickness in over 40 years, removing a key regulatory hurdle and enhancing its commercial prospects. The stock’s sharp rise reflects optimism about the drug’s accelerated development pathway and market potential.